Related Experiment Videos
Effects of oncostatin M and tamoxifen on human melanoma cells
P Gibbs1, Q Chen, W A Robinson
1Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia.
Abstract:
New agents are required in the treatment of malignant melanoma, to be used alone or in combination with established therapies. Oncostatin M (OSM), a member of the gp130 family of cytokines, has previously been shown to inhibit the growth of melanoma cell lines. Tamoxifen (TAM) is widely used in the treatment of melanoma, typically in combination with chemo- and/or immunotherapy. A component of the antitumour activity of TAM is via modulation of transforming growth factor-beta (TGF beta) which has previously been shown to be synergistic with OSM in vitro. To further investigate the clinical potential of OSM, alone and in combination with TAM, set concentrations of each were added to nine fresh and two well-established melanoma cell lines. The proliferation of seven of the 11 cell lines was inhibited by OSM, while two were unresponsive at the dose range tested. Of particular interest was the finding that the growth of two of the cell lines was significantly stimulated at low doses of OSM. The combination of OSM with TAM produced widely divergent results, most frequently resembling the effects of OSM alone. No synergism between the two was evident in any of the cell lines tested. Our results indicate that a combination of OSM and TAM in clinical trials needs further evaluation before it can be recommended. Furthermore, while OSM alone may be useful in the treatment of melanoma, this may be complicated by the possibility of stimulating tumour growth in some instances.
Insights
Oncostatin M (OSM) showed potential in inhibiting melanoma cell growth, but sometimes stimulated it. Combining OSM with Tamoxifen (TAM) did not yield synergistic effects, requiring further evaluation for clinical use.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Malignant melanoma treatment requires novel therapeutic agents.
- Oncostatin M (OSM), a gp130 family cytokine, inhibits melanoma cell lines.
- Tamoxifen (TAM) is used in melanoma treatment, modulating transforming growth factor-beta (TGF-β), which can synergize with OSM.
Purpose of the Study:
- To investigate the clinical potential of Oncostatin M (OSM) alone and in combination with Tamoxifen (TAM) for melanoma treatment.
- To assess the effects of OSM and TAM on melanoma cell proliferation in vitro.
Main Methods:
- Eleven melanoma cell lines (nine fresh, two established) were treated with varying concentrations of OSM and TAM.
- Cell proliferation was measured to evaluate the inhibitory or stimulatory effects of the agents.
Main Results:
- OSM inhibited the proliferation of seven out of eleven melanoma cell lines.
- Two cell lines showed significant growth stimulation at low OSM doses.
- The combination of OSM and TAM did not demonstrate synergistic effects; results often mirrored OSM's effects alone.
- No synergy was observed between OSM and TAM in any tested cell line.
Conclusions:
- OSM alone may have therapeutic utility in melanoma, but its potential to stimulate tumor growth requires careful consideration.
- The combination of OSM and TAM did not show synergistic benefits and requires further investigation before clinical recommendation.
- Further evaluation is needed to determine the precise role and optimal application of OSM in melanoma therapy.